Literature DB >> 8671900

Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study.

G Coen1, S Mazzaferro, P Ballanti, D Sardella, S Chicca, M Manni, E Bonucci, F Taggi.   

Abstract

BACKGROUND: Renal osteodystrophy has been studied less extensively in predialysis than in dialysis patients. Different types or histological patterns in their natural evolution from moderate to advanced severity of renal insufficiency are only partially known, with special regard to adynamic bone disease and its relationship with osteomalacia.
METHODS: We conducted a cross-sectional retrospective study on 76 unselected patients with chronic renal failure undergoing conservative treatment, with a wide range of severity of renal insufficiency. All the patients were subjected to bone biopsy for histological and histomorphometric evaluation. The patients, 44 males and 32 females ranging in age from 18 to 72 years and with serum creatinine 1.2-11.4 mg/dl, had not been exposed to aluminium-containing drugs and had never been treated with vitamin D or calcitriol.
RESULTS: Ten patients had normal bone, nine were diagnosed with adynamic bone disease, 26 with mild mixed osteodystrophy, seven with predominant osteomalacia, 22 with advance mixed osteodystrophy, and two with predominant hyperparathyroidism. Patients with adynamic bone disease had less severe chronic renal failure than the other pathological subgroups, intact PTH above the upper limit of normal, normocalcaemia, and reduced serum osteocalcin in line with a significantly lower ObS/BS. Osteomalacia was found in a more advanced stage of chronic renal failure with relative hypocalcaemia and more severe metabolic acidosis. A creatinine clearance of 20 ml/min served as a clear demarcation between this histological group and adynamic bone disease.
CONCLUSIONS: It is postulated that adynamic bone disease is a form of renal osteodystrophy, separate from osteomalacia, appearing when bone resistance to PTH develops, probably a transient stage to more hyperparathyroid histological classes with increasing severity of chronic renal failure.

Entities:  

Mesh:

Year:  1996        PMID: 8671900     DOI: 10.1093/oxfordjournals.ndt.a027404

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  34 in total

Review 1.  Chronic renal disease.

Authors:  Malvinder S Parmar
Journal:  BMJ       Date:  2002-07-13

2.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

3.  Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality.

Authors:  Astrid Starke; Alf Corsenca; Thomas Kohler; Johannes Knubben; Marius Kraenzlin; Daniel Uebelhart; Rudolf P Wüthrich; Brigitte von Rechenberg; Ralph Müller; Patrice M Ambühl
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 8.237

4.  Annual change in bone mineral density in predialysis patients with chronic renal failure: significance of a decrease in serum 1,25-dihydroxy-vitamin D.

Authors:  Naoko Obatake; Eiji Ishimura; Takao Tsuchida; Kaname Hirowatari; Hiroshi Naka; Yasuo Imanishi; Takami Miki; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

Review 5.  Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Authors:  Ziad Massy; Tilman Drueke
Journal:  J Nephrol       Date:  2017-04-12       Impact factor: 3.902

6.  Inflammation and the bone-vascular axis in end-stage renal disease.

Authors:  L Viaene; G J Behets; S Heye; K Claes; D Monbaliu; J Pirenne; P C D'Haese; P Evenepoel
Journal:  Osteoporos Int       Date:  2015-08-21       Impact factor: 4.507

Review 7.  Role of bone biopsy in stages 3 to 4 chronic kidney disease.

Authors:  Anca Gal-Moscovici; Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

Review 8.  Consequences and therapy of the metabolic acidosis of chronic kidney disease.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Pediatr Nephrol       Date:  2010-06-05       Impact factor: 3.714

9.  Vitamin D receptor activators can protect against vascular calcification.

Authors:  Suresh Mathew; Richard J Lund; Lala R Chaudhary; Theresa Geurs; Keith A Hruska
Journal:  J Am Soc Nephrol       Date:  2008-04-30       Impact factor: 10.121

Review 10.  Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.

Authors:  S N Salam; A Khwaja; M E Wilkie
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.